Optimising management of chronic heart failure

The Lancet

Volumn 374, Issue 9704, 2009, Pages 1808-1809

  Krum, Henry ^a  

^a Cardiovascular Research Centre   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; CAPTOPRIL; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOSARTAN; NEUROHORMONE; RENIN INHIBITOR;

ARTICLE; DIABETIC NEUROPATHY; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERANCE; FUNCTIONAL STATUS; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DYSFUNCTION; LOW DRUG DOSE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC HEART FAILURE;

EID: 71549166628     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61992-9     Document Type: Note

References (11)

1. Pitt B., Poole-Wilson P.A., Segal R., et al., on behalf of the ELITE II investigators. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial-the Losartan Heart Failure Survival Study ELITE II. Lancet 355 (2000) 1582-1587
2. Dickstein K., Kjekshus J., and the OPTIMAAL Steering Committee for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Lancet 360 (2002) 752-760
3. Brenner B.M., Cooper M.E., de Zeeuw D., et al., for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
4. Dahlöf B., Devereux R.B., Kjeldsen S.E., et al., for the LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
5. Konstam M.A., Neaton J.D., Dickstein K., et al., for the HEAAL Investigators. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet (2009) 10.1016/S0140-6736(09)61913-9 published online Nov 17.
6. Brunner-La Rocca H.P., Weilenmann D., Kiowski W., Maly F.E., Candinas R., and Follath F. Within-patient comparison of effects of different dosages of enalapril on functional capacity and neurohormone levels in patients with chronic heart failure. Am Heart J 138 (1999) 654-662
7. Pacher R., Stanek B., Globits S., et al. Effects of two different enalapril dosages on clinical, haemodynamic and neurohumoral response of patients with severe congestive heart failure. Eur Heart J 17 (1996) 1223-1232
8. Gullestad L., Aukrust P., Ueland T., et al. Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol 34 (1999) 2061-2067
9. The NETWORK Investigators. Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. Eur Heart J 19 (1998) 481-489
10. Packer M., Poole-Wilson P.A., Armstrong P.W., et al., on behalf of the ATLAS Study Group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 100 (1999) 2312-2318
11. Nanas J.N., Alexopoulos G., Anastasiou-Nana M.I., et al., for the High Enalapril Dose Study Group. Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study. J Am Coll Cardiol 36 (2000) 2090-2095